PL3346273T3 - Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie - Google Patents

Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie

Info

Publication number
PL3346273T3
PL3346273T3 PL17172220.0T PL17172220T PL3346273T3 PL 3346273 T3 PL3346273 T3 PL 3346273T3 PL 17172220 T PL17172220 T PL 17172220T PL 3346273 T3 PL3346273 T3 PL 3346273T3
Authority
PL
Poland
Prior art keywords
novel
peptides derived
enantiomeric peptides
enantiomeric
derived
Prior art date
Application number
PL17172220.0T
Other languages
English (en)
Inventor
Dieter Willbold
Oleksander Brener
Susanne Aileen Funke
Luitgard Nagel-Steger
Antonia Nicole KLEIN
Dirk Bartnik
Original Assignee
Priavoid Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priavoid Gmbh filed Critical Priavoid Gmbh
Publication of PL3346273T3 publication Critical patent/PL3346273T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
PL17172220.0T 2012-09-14 2013-09-13 Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie PL3346273T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung

Publications (1)

Publication Number Publication Date
PL3346273T3 true PL3346273T3 (pl) 2023-04-11

Family

ID=49354628

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17172220.0T PL3346273T3 (pl) 2012-09-14 2013-09-13 Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie

Country Status (9)

Country Link
US (3) US20150307552A1 (pl)
EP (2) EP3346273B1 (pl)
JP (2) JP6345670B2 (pl)
CN (2) CN107556375A (pl)
DE (1) DE102012108598A1 (pl)
DK (2) DK2895867T3 (pl)
ES (2) ES2768264T3 (pl)
PL (1) PL3346273T3 (pl)
WO (1) WO2014041115A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DE102015003503A1 (de) 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
DE102015003676A1 (de) 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz
RU2020114744A (ru) * 2017-10-02 2021-11-09 Седарс-Синаи Медикал Сентер Способы и композиции для эффективной доставки через множество биобарьеров
DE102021121435A1 (de) * 2021-08-18 2023-02-23 Priavoid Gmbh Aß-BINDENDE SUBSTANZEN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355374T1 (de) * 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
JPWO2002081515A1 (ja) * 2001-04-03 2004-07-29 協和醗酵工業株式会社 インスリン様増殖因子結合蛋白質
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US20070092508A1 (en) 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
WO2010062570A2 (en) * 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
DE102010017130B4 (de) 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
EP2834643B1 (de) * 2012-04-05 2019-10-23 Forschungszentrum Jülich GmbH Verfahren zur behandlung von blut, blutprodukten und organen
WO2013150127A2 (de) * 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung

Also Published As

Publication number Publication date
JP2015531348A (ja) 2015-11-02
ES2768264T3 (es) 2020-06-22
DK2895867T3 (da) 2020-02-03
JP2018141008A (ja) 2018-09-13
ES2938773T3 (es) 2023-04-14
EP2895867B1 (de) 2019-10-23
US20150307552A1 (en) 2015-10-29
CN104704371A (zh) 2015-06-10
JP6345670B2 (ja) 2018-06-20
WO2014041115A3 (de) 2014-06-26
EP3346273A1 (de) 2018-07-11
WO2014041115A2 (de) 2014-03-20
US10167318B2 (en) 2019-01-01
JP6611858B2 (ja) 2019-11-27
EP3346273B1 (de) 2023-01-04
US10889618B2 (en) 2021-01-12
CN107556375A (zh) 2018-01-09
DE102012108598A1 (de) 2014-04-10
DK3346273T3 (da) 2023-02-27
CN104704371B (zh) 2017-11-07
EP2895867A2 (de) 2015-07-22
US20190085030A1 (en) 2019-03-21
US20170313744A1 (en) 2017-11-02
EP3346273A8 (de) 2018-08-29

Similar Documents

Publication Publication Date Title
IL283139A (en) Proline-locked clamped peptides and their uses
HK1253343A1 (zh) 新穎縮肽及其用途
EP2870170A4 (en) NOVEL PEPTIDES AND THEIR USE
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
SG11201500111VA (en) Peptides and uses thereof
HK1204772A1 (en) Aromatic-cationic peptides and uses of same
SG11201501646PA (en) Peptides and their uses
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
EP2793921A4 (en) PEPTIDES DERIVED FROM SAPOSIN A AND USES THEREOF
EP2855506A4 (en) PEPTIDE AND ASSOCIATED USE
PL3346273T3 (pl) Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
HK1209138A1 (en) Peptides
HK1206977A1 (en) Aromatic-cationic peptides and uses of same
GB201204868D0 (en) Peptides
GB201200555D0 (en) Peptide
EP2918600A4 (en) NEW PEPTIDE AND ITS USE
SG11201502980VA (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
GB201223114D0 (en) Novel peptide
HUE036243T2 (hu) PSF1-származék peptid
GB201214769D0 (en) Methodsa and peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides